Surgery pp 1965-1984 | Cite as

Principles of Cancer Surgery

  • John H. Donohue


Surgery remains the single most effective modality for treating most malignancies. Solid tumors must be localized to allow complete resection that offers a patient the potential for curative treatment. Although adjuvant therapies have improved disease-free and overall survivals, most notably in breast1 and colorectal2 cancers, these treatments are effective in only a minority of patients.


Breast Cancer Gastric Cancer Sentinel Lymph Node Familial Adenomatous Polyposis Cutaneous Melanoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    NIH Consensus Development Panel. National Institute of Health consensus development conference statement: adjuvant therapy for breast cancer, November 1–3, 2000. J Natl Cancer Inst 2001;93:979–989.CrossRefGoogle Scholar
  2. 2.
    MacDonald JS. Adjuvant therapy of colon cancer. CA Cancer J Clin 1999;49:202–219.PubMedCrossRefGoogle Scholar
  3. 3.
    Fearon ER, Vogelstein B. A genetic model for colorectal tumor-igenesis. Cell 1990;61:759–767.PubMedCrossRefGoogle Scholar
  4. 4.
    Greene FL, Page DL, Fleming ID, et al., eds. AJCC Cancer Staging Manual, 6th ed. New York: Springer-Verlag, 2002.Google Scholar
  5. 5.
    O’Connell JB, Maggard MA, Ko KY. Colon cancer survival rates with the new American Joint Committee on Cancer, 6th ed. Staging. J Natl Cancer Inst 2004;96:1420–1425.PubMedGoogle Scholar
  6. 6.
    Oken M, Creech R, Tormey D, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649–655.PubMedCrossRefGoogle Scholar
  7. 7.
    Dripps R, Lamont A, Eckenhoff J. The role of anesthesia in surgical mortality. JAMA 1961;178:261–266.PubMedGoogle Scholar
  8. 8.
    The Veterans Affairs Total Parenteral Nutrition Cooperative Study Group. Preoperative total parenteral nutrition in surgical patients. N Engl J Med 1991;325:525–531.Google Scholar
  9. 9.
    von Meyenfeldt M, Meyerink W, Soeters P, et al. Perioperative nutritional support results in a reduction of major postoperative complications, especially in high risk patients. Gastroenterology 1991;100:A5553.Google Scholar
  10. 10.
    Heslin M, Latkany L, Leung D, et al. A prospective randomized trial of early enteral feeding after resection of upper gastrointestinal malignancy. Ann Surg 1997;226:567–580.PubMedCrossRefGoogle Scholar
  11. 11.
    Einhorn L. Testicular cancer as a model for a curable neoplasm: the Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1981;41:3275–3280.PubMedGoogle Scholar
  12. 12.
    Willilams S, Birch R, Einhorn L, et al. Treatment of disseminated term-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987;316:1435–1440.Google Scholar
  13. 13.
    Nigro N, Vaitkevicius V, Considine B. Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum 1974;17:354–356.PubMedCrossRefGoogle Scholar
  14. 14.
    Fuchshuber P, Rodriquez-Bigas M, Weber T, et al. Anal canal and perianal epidermoid cancers. J Am Coll Surg 1997;185:494–505.PubMedGoogle Scholar
  15. 15.
    Minsky B, Cohen A, Kemeny N, et al. Enhancement of radiation-induced downstaging of rectal cancer by fluorouracil and high-dose leucovorin chemotherapy. J Clin Oncol 1992;10:79–84.PubMedGoogle Scholar
  16. 16.
    Gunderson LL, Nelson H, Martenson JA, et al. Locally advanced primary colorectal cancer: intraoperative electron and external beam irradiation ± 5FU. Int J Radiat Oncol Biol Phys 1 1997;137:601–614.CrossRefGoogle Scholar
  17. 17.
    Allee P, Tepper J, Gunderson L, et al. Postoperative radiation therapy for incompletely resected colorectal carcinoma. Int J Radiat Oncol Biol Phys 1989;17:1171–1176.PubMedGoogle Scholar
  18. 18.
    Oates G, Stenning S, Harcastle J, et al. Randomised trial of surgery alone versus radiotherapy followed by surgery for potentially operable locally advanced rectal cancer: Medical Research Council Rectal Cancer Working Party. Lancet 1996;348:1605–1610.CrossRefGoogle Scholar
  19. 19.
    Pahlman L, Glimelius B. Improved survival with preoperative radiotherapy in resectable rectal cancer: Swedish Rectal Cancer Trial. N Engl I Med 1997;336:980–987.CrossRefGoogle Scholar
  20. 20.
    Krook J, Moertel C, Gunderson L, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991;324:709–715.PubMedGoogle Scholar
  21. 21.
    Miyoshi Y, Nagase H, Ando H, et al. Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene. Hum Mol Genet 1992;1:229–233.PubMedCrossRefGoogle Scholar
  22. 22.
    Solomon E, Voss R, Hall V, et al. Chromosome 5 allele loss in human colorectal carcinomas. Nature (Lond) 1987;328:616–619.PubMedCrossRefGoogle Scholar
  23. 23.
    Nagase H, Miyoshi Y, Horii A, et al. Correlation between the location of germ-line mutations in the APC gene and the number of colorectal polyps in familial adenomatous polyposis patients. Cancer Res 1992;52:4055–4057.PubMedGoogle Scholar
  24. 24.
    Moertel C, Hill J, Adson M. Surgical management of multiple polyposis. The problem of cancer in the retained bowel segment. Arch Surg 1970;100;521–526.PubMedGoogle Scholar
  25. 25.
    Wu JS, Paul P, McGannon EA, Church JM. APC genotype, polyp number, and surgical options in familial adenomatous polyposis. Ann Surg 1998;227:57–62.PubMedCrossRefGoogle Scholar
  26. 26.
    Bertario L, Russo A, Radice P, et al. Genotype and phenotype factors as determinants for rectal stump cancer in patients with familial adenomatous polyposis. Ann Surg 2000;231:438–443.CrossRefGoogle Scholar
  27. 27.
    Ambroze W Jr, Dozois R, Pemberton J, et al. Familial adenomatous polyposis: results following ileal pouch-anal anastomosis and ileorectostomy. Dis Colon Rectum 1992;35:12–15.PubMedCrossRefGoogle Scholar
  28. 28.
    Ekborn A, Helmick C, Zack M, et al. Ulcerative colitis and colorectal cancer: a population-based study. N Engl J Med 1990;323:1228–1233.Google Scholar
  29. 29.
    Taylor B, Pemberton J, Carpenter H, et al. Dysplasia in chronic ulcerative colitis: implications for colonoscopic surveillance. Dis Col Rectum 1992;35:950–956.CrossRefGoogle Scholar
  30. 30.
    Lairmore T, Howe J, Korte J, et al. Familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2B map to the same region of chromosome 10 as multiple endocrine neoplasia type 2A. Genomics 1991;9:181–192.PubMedCrossRefGoogle Scholar
  31. 31.
    Mulligan L, Ponder B. Genetic basis of endocrine disease: multiple endocrine neoplasia type 2. J Clin Endocrinol Metab 1995;80:1989–1995.PubMedCrossRefGoogle Scholar
  32. 32.
    Carlson K, Dou S, Chi D, et al. Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci U S A 1994;91:1579–1583.PubMedCrossRefGoogle Scholar
  33. 33.
    Wells S Jr, Chi D, Toshima K, et al. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg 1994;220:237–247.PubMedCrossRefGoogle Scholar
  34. 34.
    Hartmann LC, Sellers SA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 2001;93:1633–1637.PubMedCrossRefGoogle Scholar
  35. 35.
    Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-l Study. J Natl Cancer Inst 1998;90:1371–1388.PubMedCrossRefGoogle Scholar
  36. 36.
    Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from Italian randomized trial among hysterectomised women. Lancet 1998;352:93–97.PubMedGoogle Scholar
  37. 37.
    Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998;352:98–101.PubMedGoogle Scholar
  38. 38.
    King M-C, Wieand S, Hale K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 2001;286:2251–2256.PubMedCrossRefGoogle Scholar
  39. 39.
    Kline T, Joshi L, Neal H. Fine-needle aspiration of the breast: diagnosis and pitfalls—a review of 3545 cases. Cancer (Phila) 1979-44:1458–1464.Google Scholar
  40. 40.
    Jackman R, Nowels K, Shepard M, et al. Stereotaxic large-core needle biopsy of 450 nonpalpable breast lesions with surgical correlation in lesions with cancer or atypical hyperplasia. Radiology 1994;193:91–95.PubMedGoogle Scholar
  41. 41.
    Parker S, Burbank F, Jackman R, et al. Percutaneous large-core breast biopsy: a multi-institutional study. Radiology 1994;193:359–364.PubMedGoogle Scholar
  42. 42.
    Baccarani U, Carroll B, Hiatt J, et al. Comparison of laparoscopic and open staging in Hodgkin disease. Arch Surg 1998;133:517–522.PubMedCrossRefGoogle Scholar
  43. 43.
    Burke E, Karpeh M, Conlon K, et al. Laparoscopy in the management of gastric adenocarcinoma. Ann Surg 1997;225:262–267.PubMedCrossRefGoogle Scholar
  44. 44.
    Fernandez-del Castillo C, Warshaw A. Laparoscopy for staging in pancreatic carcinoma. Surg Oncol 1993;2(suppl 1):25–29.PubMedCrossRefGoogle Scholar
  45. 45.
    Makary M, Warshaw A, Centeno B, et al. Implications of peritoneal cytology for pancreatic cancer management. Arch Surg 1998;133:361–365.PubMedCrossRefGoogle Scholar
  46. 46.
    Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002;2347:1227–1232.CrossRefGoogle Scholar
  47. 47.
    Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002;347:1233–1241.PubMedCrossRefGoogle Scholar
  48. 48.
    Poggi MM, Danforth DN, Sciuto LC, et al. Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy. The National Cancer Institute randomized trial. Cancer (Phila) 2003;98:697–702.PubMedCrossRefGoogle Scholar
  49. 49.
    van Dongen JA, Voogd AC, Fentiman IS, et al. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst 2000;92:1143–1150.PubMedCrossRefGoogle Scholar
  50. 50.
    Blichert-Toft M, Rose C, Andersen JA, et al. Danish randomized trial comparing breast conservation therapy with mastectomy: six years of life-table analysis. J Natl Cancer Inst Monogr 1992;11:19–25.PubMedGoogle Scholar
  51. 51.
    Consensus statement: treatment of early-stage breast cancer. NIH Consensus Development Conference, June 18–21, 1990, vol 8, no. 6. Bethesda, MD: National Institutes of Health, 1990:1–19.Google Scholar
  52. 52.
    Veronesi U, Cascinelli N, Adamus J, et al. This stage I primary cutaenous malignant melanoma: comparison of excision with margins of 1 or 3cm. N Engl J Med 1988;318:1159–1162.PubMedGoogle Scholar
  53. 53.
    Balch C, Urist M, Karakousis C, et al. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4): results of a multi-institutional randomized surgical trial. Ann Surg 1993;218:262–269.PubMedCrossRefGoogle Scholar
  54. 54.
    Williams N, Dixon M, Johnston D. Reappraisal of the 5 centimeter rule of distal excision for carcinoma of the rectum: a study of distal intramural spread and a patients’ survival. Br J Surg 1983;70:150–154.PubMedCrossRefGoogle Scholar
  55. 55.
    Quirke P, Durdey P, Dixon M, et al. Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision. Lancet 1986;2:996–999.PubMedCrossRefGoogle Scholar
  56. 56.
    Bozzetti F, Marubini E, Bonfanti G, et al. Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Ann Surg 1999;230:170–178.PubMedCrossRefGoogle Scholar
  57. 57.
    Balch C, Soong S, Milton G. A comparison of prognostic factors and surgical results in 1,786 patients with localized (stage I) melanoma treated in Alabama, USA, and New South Wales, Australia. Ann Surg 1982;196:677–684.PubMedCrossRefGoogle Scholar
  58. 58.
    Veronesi U, Adamus J, Bandiera D, et al. Delayed regional lymph node dissection in Stage I melanoma of the skin of the lower extremities. Cancer (Phila) 1982;49:2420–2430.PubMedCrossRefGoogle Scholar
  59. 59.
    Sim F, Taylor W, Pritchard D, et al. Lymphadenectomy in the management of Stage I malignant melanoma: a prospective randomized study. Mayo Clin Proc 1986;61:697–705.PubMedGoogle Scholar
  60. 60.
    Balch C, Soong S, Bartolucci A, et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 1996;224:225–266.CrossRefGoogle Scholar
  61. 61.
    Morton D, Wen D, Wong J, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392–399.PubMedGoogle Scholar
  62. 62.
    Krag D, Meijer S, Weaver D, et al. Minimal-access surgery for staging of malignant melanoma. Arch Surg 1995;130:654–660.PubMedGoogle Scholar
  63. 63.
    Cochran AJ, Balda B-R, Starz H, et al. The Augsburg Consensus. Techniques of lymphatic mapping, sentinel lymphadenectomy, and completion lymphadenectomy in cutaneous malignancies. Cancer (Phila) 2000;89:236–241.PubMedCrossRefGoogle Scholar
  64. 64.
    Cascinelli N, Belli F, Santinami M, et al. Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience. Ann Surg Oncol 2000;7:469–474.PubMedCrossRefGoogle Scholar
  65. 65.
    Morton DL, Hoon SDB, Cochran AJ, et al. Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases. Ann Surg 2003;238:538–550.PubMedGoogle Scholar
  66. 66.
    Gershenwald J, Colome M, Lee J, et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with Stage I or II melanoma. J Clin Oncol 1998;16:2253–2260.PubMedGoogle Scholar
  67. 67.
    Noguchi Y, Imada T, Matsumoto A, et al. Radical surgery for gastric cancer: a review of the Japanese experience. Cancer (Phila) 1989;64:2053–2062.PubMedCrossRefGoogle Scholar
  68. 68.
    Noda N, Sasako M, Yamaguchi N, et al. Ignoring small lymph nodes can be a major cause of staging error in gastric cancer. Br J Surg 1998;85:831–834.PubMedCrossRefGoogle Scholar
  69. 69.
    Dent D, Madden M, Price S. Randomized comparison of Rl and R2 gastrectomy for gastric carcinoma. Br J Surg 1988;75:110–112.PubMedCrossRefGoogle Scholar
  70. 70.
    Robertson C, Chung S, Woods S, et al. A prospective randomized trial comparing Rl subtotal gsatrectomy with R3 total gastrectomy for antral cancer. Ann Surg 1994;220:176–182.PubMedCrossRefGoogle Scholar
  71. 71.
    Siewert JR, Bottcher K, Stein HJ, et al. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 1998;228:449–461.PubMedCrossRefGoogle Scholar
  72. 72.
    Hartgrink HH, van de Velde CJH, Putter H, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch Gastric Cancer Group Trial. J Clin Oncol 2004;22:2069–2077.PubMedCrossRefGoogle Scholar
  73. 73.
    Cuschieri A, Weeden S, Fielding J, et al. Patient survival after Dl and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Br J Cancer 1999;79:1522–1530.PubMedCrossRefGoogle Scholar
  74. 74.
    Fisher B. Laboratory and clinical research in breast cancer—a personal adventure: the David A. Karnofsky Memorial Lecture. Cancer Res 1980;40:3863–3874.PubMedGoogle Scholar
  75. 75.
    Fischer B, Jeong J-H, Anderson S, et al. Twenty-five year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 2002;347:567–575.CrossRefGoogle Scholar
  76. 76.
    Chontos A, Maher D, Ratzer E, et al. Axillary lymph node dissection: is it required in T1a breast cancer? Am J Surg 1996;172:501–505.CrossRefGoogle Scholar
  77. 77.
    McGee Y, Youmans R, Clingan F, et al. The value of axillary dissection in T1a breast cancer. Am J Surg 1996;172:501–505.PubMedCrossRefGoogle Scholar
  78. 78.
    Barth A, Craig P, Silverstein M. Predictors of axillary lymph node metastases in patients with T1 breast carcinoma. Cancer (Phila) 1997;79:1918–1922.PubMedCrossRefGoogle Scholar
  79. 79.
    Giuliano A, Jones R, Brennan M, et al. Sentinel lymphadenectomy in breast cancer. J Clin Oncol 1997;15:2345–2350.PubMedGoogle Scholar
  80. 80.
    Veronesi U, Paganelli G, Balimberti V, et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph nodes. Lancet 1997;349:1864–1867.PubMedCrossRefGoogle Scholar
  81. 81.
    Ollila D, Brennan M, Giuliano A. Therapeutic effect of sentinel lymphadenectomy in T1 breast cancer. Arch Surg 1998;133:647–651.PubMedCrossRefGoogle Scholar
  82. 82.
    Scheele J, Stang R, Altendorf-Hofmann A, et al. Resection of colorectal liver metastases. World J Surg 1995;19:59–71.PubMedCrossRefGoogle Scholar
  83. 83.
    Fong Y, Cohen A, Fortner J, et al. Liver resection for colorectal metstases. J Clin Oncol 1997;15:938–946.PubMedGoogle Scholar
  84. 84.
    Hughes KS, Simon R, Songhorabodi S, et al. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of indications for resection. Surgery (St. Louis) 1988;103:278–288.Google Scholar
  85. 85.
    Nordlinger B, Jaeck D, Guiguet M, et al. Multicentric retrospective study by the French Surgical Association. In: Nordlinger B, Jaeck D, eds. Treatment of Hepatic Metastases of Colorectal Cancer. Paris: Springer-Verlag, 1992, pp 129–146.Google Scholar
  86. 86.
    Wilson S, Adson M. Surgical treatment of hepatic metastases from colorectal cancers. Arch Surg 1976;111:330–334.PubMedGoogle Scholar
  87. 87.
    Jamison R, Donohue J, Nagorney D, et al. Hepatic resection for metastatic colorectal cancer results in cure for some patients. Arch Surg 1997;132:505–511.PubMedGoogle Scholar
  88. 88.
    Scheele J, Rudroff C, Altendorf-Hofmann A. Resection of colorectal liver metastases revisited. J Gastrointest Surg 1997;1:408–422.PubMedCrossRefGoogle Scholar
  89. 89.
    Fernandez-Trigo V, Shamsa F, Sugarbaker P, et al. Repeat liver resections from colorectal metastasis. Surgery (St. Louis) 1995;117:296–304.PubMedCrossRefGoogle Scholar
  90. 90.
    Neeleman N, Andersson R. Repeated liver resection for recurrent liver cancer. Br J Surg 1996;83:893–901.PubMedCrossRefGoogle Scholar
  91. 91.
    Adam R, Bismuth H, Castaing D, et al. Repeat hepatectomy for colorectal liver metastases. Ann Surg 1997;225:51–62.PubMedCrossRefGoogle Scholar
  92. 92.
    Erce C, Parks RW. Interstitial ablative techniques for hepatic tumors. Br J Surg 2003;90:272–289.PubMedCrossRefGoogle Scholar
  93. 93.
    Abdalla EK, Vauthey J-N, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004;239:818–827.PubMedCrossRefGoogle Scholar
  94. 94.
    Bismuth H, Adam R, Levi F, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherpay. Ann Surg 1996;224:509–522.PubMedCrossRefGoogle Scholar
  95. 95.
    Adam R, Avisar E, Ariche A, et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal [liver] metastases. Ann Surg Oncol 2001;8:347–353.PubMedCrossRefGoogle Scholar
  96. 96.
    Tanaka K, Adam R, Shimada H, et al. Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver. Br J Surg 2003;90:963–969.PubMedCrossRefGoogle Scholar
  97. 97.
    McCormack P, Burg M, Bains M, et al. Lung resection for colorectal metastases: 10-year results. Arch Surg 1992;127:1403–1406.PubMedGoogle Scholar
  98. 98.
    McAfee M, Allen M, Trastek V, et al. Colorectal lung metastases: results of surgical excision. Ann Thorac Surg 1992;53:780–786.PubMedCrossRefGoogle Scholar
  99. 99.
    Martini N, McCormack P, Bains M, et al. Surgery for solitary and multiple pulmonary metastases. N Y State J Med 1978;78:1711–1714.PubMedGoogle Scholar
  100. 100.
    Creagan E, Fleming T, Edmonson J, et al. Pulmonary resection for metastatic nonosteogenic sarcoma. Cancer (Phila) 1979;44:1908–1912.PubMedCrossRefGoogle Scholar
  101. 101.
    Putnam J, Roth J, Wesley M, et al. Analysis of prognostic factors in patients undergoing resection of pulmonary metastases from soft tissue sarcomas. J Thorac Cardiovasc Surg 1984;87:260–268.PubMedGoogle Scholar
  102. 102.
    Griffiths C. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 1975;42:101–104.PubMedGoogle Scholar
  103. 103.
    Vogl S, Pagano M, Kaplan B, et al. Cisplatin based combination chemotherapy for advanced ovarian cancer: high overall response rate with curative potential only in women with small tumor burdens. Cancer (Phila) 1983;51:2024–2030.PubMedCrossRefGoogle Scholar
  104. 104.
    Pohl R, Dallenbach-Hellweg G, Plugge T, et al. Prognostic parameters in patients with advanced ovarian malignant tumors. Eur J Gynaecol Oncol 1984;3:160–169.Google Scholar
  105. 105.
    Omura G, Bundy B, Berek J, et al. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a gynecologic oncology study group. J Clin Oncol 1989;7:457–465.PubMedGoogle Scholar
  106. 107.
    Hoskins W, Bundy B, Thigpen J, et al. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a gynecologic oncology group study. Gynecol Oncol 1992;47:159–166.PubMedCrossRefGoogle Scholar
  107. 107.
    Hoskins W, McGuire W, Brady M, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994;170:974–980.PubMedGoogle Scholar
  108. 108.
    Curtin J, Malik R, Venkatraman E, et al. Stage IV ovarian cancer: impact on surgical debulking. Gynecol Oncol 1997;64:9–12.PubMedCrossRefGoogle Scholar
  109. 109.
    Boente M, Chi D, Hoskins W. The role of surgery in the management of ovarian cancer: primary and interval cytoreductive surgery. Semin Oncol 1998;25:326–334.PubMedGoogle Scholar
  110. 110.
    Moertel C. An odyssey in the land of small tumors (Karnofsky Memorial Lecture). J Clin Oncol 1987;5:1502–1522.PubMedGoogle Scholar
  111. 111.
    Iwatsuki S, Tzakis A, Todo S, et al. Liver transplantation for metastatic hepatic malignancy. Hepatology 1993;18:723.Google Scholar
  112. 112.
    Lang H, Oldhafer K, Weinmann A, et al. Liver transplantation for metastatic neuroendocrine tumors. Ann Surg 1997;225:355–364.CrossRefGoogle Scholar
  113. 113.
    Le Treut Y, Delpero J, Dousset B, et al. Results of liver transplantation in the treatment of metastatic neuroendocrine tumors: a 31-case French multicentric report. Ann Surg 1997;225:355–364.PubMedCrossRefGoogle Scholar
  114. 114.
    Sarmiento JM, Heywood G, Rubin J, et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 2003;197:29–37.PubMedCrossRefGoogle Scholar
  115. 115.
    Chen H, Hardacre J, Uzar A, et al. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg 1998;198:88–93.CrossRefGoogle Scholar
  116. 116.
    Speer A, Cotton P, Russell R, et al. Randomized trial of endoscopic versus percutaneous stent insertion in malignant obstructive jaundice. Lancet 1978;2:57–62.Google Scholar
  117. 117.
    Shepherd H, Royle G, Ross A, et al. Endoscopic biliary endoprostheses in the palliation of malignant obstruction of the distal common bile duct: a randomized trial. Br J Surg 1988;75:1166–1168.PubMedCrossRefGoogle Scholar
  118. 118.
    Smith A, Dowsett J, Russell R, et al. Randomized trial of endoscopic stenting versus surgical bypass in malignant low bile duct obstruction. Lancet 1994;334:1655–1660.CrossRefGoogle Scholar
  119. 119.
    Davids PHP, Groen AK, Rauws EAJ, et al. Randomised trial of self-expanding metal stents versus polyethylene stents for distal malignant biliary obstruction. Lancet 1992;340:1488–1492.PubMedCrossRefGoogle Scholar
  120. 120.
    Gilbert D, DiMarino A, Jensen D, et al. Status evaluation: biliary stents. Gastrointest Endosc 1992;38:750–752.PubMedCrossRefGoogle Scholar
  121. 121.
    Deviere J, Baize M, de Toeuf J, et al. Long-term follow-up of patients with hilar malignant stricture treated by endoscopic internal biliary drainage. Gastrointest Endosc 1988;34:95–101.PubMedCrossRefGoogle Scholar
  122. 122.
    Mittal A, Windsor J, Woodfield J, et al. Matched study of three methods for palliation of malignant pyloroduodenal obstruction. Br J Surg 2004;91:205–209.PubMedCrossRefGoogle Scholar
  123. 123.
    Lillemoe K, Cameron J, Kaufman H, et al. Chemical splanchni-cectomy in patients with unresectable pancreatic cancer: a prospective, randomized trial. Ann Surg 1993;217;447–457.PubMedCrossRefGoogle Scholar
  124. 124.
    Rosenberg S, Kent H, Costa J, et al. Prospective, randomized evaluation of the role of limb-sparing surgery, radiation therapy, and adjuvant chemoimmunotherapy in the treatment of adult soft-tissue sarcomas. Surgery (St. Louis) 1978;84:62–69.PubMedGoogle Scholar
  125. 125.
    Brennan M, Shiu M, Collin C, et al. Extremity soft tissue sarcomas. Cancer Treat Symp 1985;3:71–81.Google Scholar
  126. 126.
    Eilber F, Guiliano A, Huth J, et al. Limb salvage for high grade soft tissue sarcomas of the extremity: experience at the University of California, Los Angeles. Cancer Treat Symp 1985;3:49–57.Google Scholar
  127. 127.
    Denton J, Dunham W, Salter M, et al. Preoperative regional chemotherapy and rapid-fraction irradiation for sarcomas of the soft tissue and bone. Surg Gynecol Obstet 1984;158:545–551.PubMedGoogle Scholar
  128. 128.
    Veronesi U, Bonadonna G, Zurrida S, et al. Conservation surgery after primary chemotherapy in large carcinomas of the breast. Ann Surg 1995;222:612–618.PubMedCrossRefGoogle Scholar
  129. 129.
    Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997;15:2483–2493.PubMedGoogle Scholar
  130. 130.
    Johnson C, van Heerden J, Donohue J, et al. Oncological aspects of immediate breast reconstruction following mastectomy for malignancy. Arch Surg 1989;124:819–824.PubMedGoogle Scholar
  131. 131.
    Noone R, Frazier T, Noone G, et al. Recurrence of breast carcinoma following immediate reconstruction: a 13-year review. Plast Reconstr Surg 1994;93:96–108.PubMedCrossRefGoogle Scholar
  132. 132.
    Carlson G, Bostwick J, Styblo T, et al. Skin-sparing mastectomy: oncologic and reconstructive considerations. Ann Surg 1997;225:570–578.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • John H. Donohue
    • 1
    • 2
  1. 1.Department of Surgery, Mayo Medical SchoolMayo ClinicRochesterUSA
  2. 2.Division of Gastroenterologic and General SurgeryMayo ClinicRochesterUSA

Personalised recommendations